ImmediapressCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma Di Redazione - 20 Settembre 2019 CondividiFacebook Twitter WhatsApp Linkedin Email Print Telegram